PCN94 Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece

G Gourzoulidis,M Koulentaki,A Koumarianou,E Samantas,N Androulakis,S Xynogalos,P Papakotoulas,I Boukovinas,M Karamouzis,I Souglakos,V Chotzagiannoglou,A Beletsi,G Kourlaba

doi:10.1016/j.jval.2020.08.231

PCN94 Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece

G Gourzoulidis, M Koulentaki + Show 11 more

Open Access

https://doi.org/10.1016/j.jval.2020.08.231

Copy DOI

Journal: Value in Health	Publication Date: Dec 1, 2020
License type: publisher-specific-oa

Affiliation: Metropolitan Hospital, Space Hellas (Greece), University Hospital of Heraklion, National and Kapodistrian University of Athens, Metaxa Hospital, The General Hospital of Heraklion "Venizeleio-Pananio", Theageneio General Hospital

#PRIOR Therapies For Metastatic Disease #Treatment Of Metastatic Gastric Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCN94 Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece

Full Text